Member Profile

SynCore Biotechnology Co., Ltd. (“SynCoreBio”) is a biopharmaceutial company focusing on creating values of new drug by R&D and integration of technology resources. SynCore was established in 2008 and cofounded by Sinphar Group and National Health Research Institute (NHRI). SynCore inherited Sinphar’s experiences which have been accumulated for more than 30 years in R&D, manufacturing, and international marketing. Such experiences enables SynCore to build up the comprehensive pipeline portfolio for new drug development to fulfill domestic and international market needs and to consolidate the future development.

SynCore utilizes and in-licenses the unique technologies from all over the world to develop new drugs with great marketing potential. By professional and expeditious project management, SynCore accumulates intangible assets to promote its marketing values. SynCore keeps looking for international partners actively and guarantee stable and long-term profits through strategic alliance to enrich sustainable operating energy.

Product Pipelines

Please move your mouse cursor over abbreviations with periods to see their full names.

Company Milestones

   2017 SynCoreBio receives investigational new drug (IND) clearance of SB05 (EndoTAG®-1) by the Taiwan Food and Drug Administration (TFDA) to conduct a Phase III clinical trial for the treatment of metastatic adenocarcinoma of the Pancreas.
   2018 SynCoreBio signs agreement with British Company Epipole to distribute ophthalmic diagnosis fundus cameras in Taiwan.
   2019 SynCoreBio is approved by the National Medical Product Administration (NMPA) of China to conduct Phase III Clinical trial of first-line treatment for pancreatic cancer in China.
   2021 SynCoreBio SB05 EndoTAG-1 receives the EU and CN invention patent certification.
   2021 SynCore Biotechnology Announces Final Analysis Results for Novel Pancreatic Cancer Asset, SB05PC (EndoTAG®-1).
   2022 SynCore Bio Doses First Patient In First-line Phase III Trial for SB05 (EndoTAG®-1)Pancreatic Cancer in China.
   2022 SynCore SB05PC abstract accepted at ESMO Asia Congress 2022
   2022 SynCore presented poster at ESMO Asia Congress 2022